No significant effect of orally administered chemokine receptor 1 antagonist on intercellular adhesion molecule-3 expression in relapsing-remitting multiple sclerosis patients

Multiple Sclerosis

Volumn 16, Issue 3, 2010, Pages 366-369

  Reuss R ^a,b   Schreiber, V ^a   Klein, A ^a   Infante Duarte, C ^c   Filippi, M ^d   Pabst, W ^a   Pohl, C ^e,f   Oschmann, P ^b  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b Hospital Hohe Warte   (Germany)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY HOSPITAL BONN   (Germany)

^f BAYER PHARMA AG   (Germany)

Author keywords

Chemokine receptor 1 antagonist; Flow cytometry; Intercellular adhesion molecule 3; MRI; Multiple sclerosis; Receptor cross talk

Indexed keywords

1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYL 1 PIPERAZINYL] 2 OXOETHOXY]PHENYL]UREA; CD14 ANTIGEN; CHEMOKINE RECEPTOR CCR1; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 3; PLACEBO;

ARTICLE; AUTOCRINE EFFECT; CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MULTICENTER STUDY; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ANTIGENS, CD; ANTIGENS, CD14; CELL ADHESION MOLECULES; DOUBLE-BLIND METHOD; FLOW CYTOMETRY; GERMANY; HUMANS; IMMUNOLOGIC FACTORS; INTERCELLULAR ADHESION MOLECULE-1; ITALY; LEUKOCYTES, MONONUCLEAR; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PHENYLUREA COMPOUNDS; PIPERIDINES; RECEPTORS, CCR1; TIME FACTORS; TREATMENT OUTCOME;

EID: 77949890497     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458509358188     Document Type: Article

References (11)

1. Lebedeva T., Dustin ML, Sykulev Y. ICAM-1 co-stimulates target cells to facilitate antigen presentation. Curr Opin Immunol 2005 ; 17: 251-258.
2. Montoya MC, Sancho D., Bonello G., et al. Role of ICAM-3 in the initial interaction of T lymphocytes and APCs. Nat Immunol 2002 ; 3: 159-168.
3. Audran R., Lesimple T., Delamaire M., Picot C., Van Damme J., Toujas L. Adhesion molecule expression and response to chemotactic agents of human monocyte-derived macrophages. Clin Exp Immunol 1996 ; 103: 155-160.
4. Kessel JM, Hayflick J., Weyrich AS, et al. Coengagement of ICAM-3 and Fc receptors induces chemokine secretion and spreading by myeloid leukocytes. J Immunol 1998 ; 160: 5579-5587.
5. He M., Horuk R., Moochhala SM, Bhatia M. Treatment with BX471, a CC chemokine receptor 1 antagonist, attenuates systemic inflammatory response during sepsis. Am J Physiol Gastrointest Liver Physiol 2007 ; 292: G1173 - G1180.
6. Trebst C., Srensen TL, Kivis?Currency signkk P., et al. CCR1 +/ CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis. Am J Pathol 2001 ; 159: 1701-1710.
7. Zipp F., Hartung HP, Hillert J., et al. Blockade of chemokine signaling in patients with multiple sclerosis. Neurology 2006 ; 67: 1880-1883.
8. Kraus J., Oschmann P., Engelhardt B., et al. Soluble and cell surface ICAM-1 as markers for disease activity in multiple sclerosis. Acta Neurol Scand 1998 ; 98: 102-109.
9. Fawcett J., Holness CL, Needham LA, et al. Molecular cloning of ICAM-3, a third ligand for LFA-1, constitutively expressed on resting leukocytes. Nature 1992 ; 360: 481-484.
10. Montecucco F., Burger F., Pelli G., et al. Statins inhibit Creactive protein-induced chemokine secretion, ICAM-1 upregulation and chemotaxis in adherent human monocytes. Rheumatology 2009 ; 48: 233-242.
11. Babina M., Mammeri K., Henz BM Retinoic acid up-regulates myeloid ICAM-3 expression and function in a cell-specific fashion - evidence for retinoid signaling pathways in the mast cell lineage. J Leukoc Biol 2001 ; 69: 361-372.